Michael Walker

• Directed the global commercial development portfolio of eight marketed products (including Sandoglobulin® and Vivaglobin®) and two products within R&D with team of 8 and CHF 5 million budget. • Drove product vision & strategy, for new Privigen® developed brand name, positioning, messaging, brand, collaterals and core launch campaign; also conducted market and competitive analysis, identified market development/expansion opportunities, and evaluated licensing opportunities. • Formed and developed a Glob

• Directed the marketing function for NovoSeven® in haemophilia and acquired haemophilia, and provided support for off-label sales in indications under development. • Provided marketing input into European business plans and budget development, evaluated licensing and business opportunities, coordinated annual sales conferences and annual HBU meeting (theme, agenda, activities) for staff of 100, and prioritised pricing and reimbursement applications across Europe. • Managed four direct reports (two Europ

• Drove Roche’s global business strategy for transplantation, including the immunosuppressants CellCept® and Zenapax®. • Developed global strategy for long-term use of CellCept®, supported affiliates with strategic direction and materials, developed forecast models and evaluated licensing opportunities. • Managed a CHF 12 million marketing budget, led a seven-person Global Business Team, and oversaw a local cross-functional Basel headquarters team; direct line responsibility for Medical Managers, Product M